« previous next »
Pages: [1]

Author Topic: (AAN abst.) Higher efficacy therapies may have a disproportionately larger effect in younger PwMS  (Read 95 times)

0 Members and 1 Guest are viewing this topic.

Online agate

  • Administrator
  • *****
  • Posts: 9842
  • MS diagnosed 1980
  • Location: Pacific Northwest
(AAN abst.) Higher efficacy therapies may have a disproportionately larger effect in younger PwMS
« on: May 11, 2019, 03:15:44 pm »
Abstract of a presentation at the annual AAN conference (Philadelphia, May 4-10, 2019) entitled "Higher efficacy therapies appear to have a disproportionately larger effect in younger patients with multiple sclerosis" from researchers at the University of Colorado:


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-004406.pdf
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
64 Views 		Last post November 07, 2016, 03:50:53 pm
by agate
0 Replies
158 Views 		Last post March 16, 2018, 11:51:28 am
by agate
2 Replies
231 Views 		Last post September 08, 2019, 04:17:59 pm
by agate
1 Replies
91 Views 		Last post May 29, 2020, 09:45:07 pm
by agate
0 Replies
23 Views 		Last post May 24, 2022, 09:39:45 pm
by agate